Addex Therapeutics Ltd. — Form 6-K Summary
Business context and reporting period
Addex Therapeutics Ltd., a Swiss foreign private issuer, furnished this Form 6-K in September 2026. The referenced interim financial statements cover the six months ended June 30, 2026, with comparative periods in 2025, and balance-sheet information as of June 30, 2026 and December 31, 2025. The provided filing text lists the financial statements and management’s discussion and analysis as exhibits but does not include their contents.
Financial results and liquidity
The provided text does not give clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics. These cannot be assessed from the supplied excerpt.
Changes, outlook, and risks
The excerpt does not provide results for comparison with the prior period, management commentary, or company-specific guidance or outlook. It cautions that the company faces significant risks and refers investors to the risk factors in its 2025 Annual Report on Form 20-F, filed May 15, 2026, and other SEC filings. It also notes that forward-looking statements involve risks and actual results may differ materially.
Exhibits 99.1 and 99.2 are incorporated by reference into the company’s specified Form F-3 and Form S-8 registration statements, subject to subsequent filings. Exhibit 99.3 is a press release dated September 28, 2026.
Key facts for investors to verify
- Review Exhibit 99.1 for the interim financial statements and the underlying values for earnings, cash, cash flows, and liabilities.
- Review Exhibit 99.2 for management’s analysis, period comparisons, liquidity assessment, outlook, and any identified unusual items or contingencies.
- Review the September 28, 2026 press release and the referenced 2025 Form 20-F for additional company updates and risk disclosures.